News
Dassault to enhance clinical tech with Medidata acquisition
Dassault Systèmes acquired Medidata, major player in information technologies for clinical trials, for $5.5 billion. This represents to date the largest buyout in the emerging area of in silico medicine and in silico trials and "a significant milestone to address the complexity of developing personalied medicine and patient-centric experiences".
Promote adoption of In Silico Trials through EMA’s strategy on Regulatory Science to 2025
The European Medicine Agency (EMA) has recently published a document that describes its strategy until 2025. It recognizes the importance of emerging technologies in general and modelling and simulation, also known as in silico methods, in particular. However, the document tends to stress the value of in silico methods almost exclusively in connection with the reduction of animal experimentation. While we agree that this is a relevant application for such methods, it is not the only one and likely not the most impactful one for the patient and for the industry. The term In Silico Trials indicates a number of use cases, not only related to pre-clinical evaluation, but also to the reduction, refinement, and in some cases even replacement of clinical trials.
European Strategy for High Performance Computing
On the 17 June, the European Commission published a presentation explaining why they indicated High Performance Computing (HPC) as a priority area for investments, and showing some concrete examples. The document notably mentions personalised healthcare and medicines discovery among the top applications, and refers to the concept of digital twins, even if related to the transport sector. This shows that the European Commission is gradually opening to the advocating messages brought forward by the Alliance and its Members.
Member of European Parliament Nicola Caputo supports the international cooperation on in silico medicine
MEP Nicola Caputo, from the Alliance of Socialists and Democrats, agreed to sign - along with other representatives of the European Union and the American Government - the request to establish an international cooperation between regulatory agencies on the evaluation of new computer simulation technologies applied to medicine.
Digital Twin & CM&S to feature in Horizon Europe core text
On 17 April, the European Parliament adopted the partial agreements resulting from interinstitutional negotiations on the two Horizon Europe proposals, the successor to Horizon 2020.
Launch of the MOBILISE-D Project
On 11 April, the project MOBILISE-D, a project funded by the European Innovative Medicines Initiative 2 Joint Undertaking, was launched with the aim to revolutionise assessment of mobility loss using digital technology to lead to enhanced clinical trials and better clinical management.
